Retrospective Study to Evaluate the Use of Type 1 Bovine Hydrolyzed Collagen to Support Surgical Wound Healing After Spinal Surgery

Original Research | Open Access | Volume 8 | Issue 1

  • 1. William R. Hotchkiss, The Carrell Clinic Orthopedic & Sports Medicine, Dallas, Texas, USA
+ Show More - Show Less
Corresponding Authors
William R. Hotchkiss, 9301 North Central Expressway Suite 400 Dallas, Texas 7523, Tel: 214-220-2468; Email: whotchkiss@carrellclinic.com

Surgical site infection (SSI) and wound dehiscence are among the most common postoperative spinal surgery complications. Treatment can be complex, costly, and may require hospital readmission. Type 1 Hydrolyzed Collagen (T1HC) powder can be used during surgery to support the healing environment of the surgical wound. This study is a retrospective review of 154 patients who underwent spinal surgery using CellerateRX ® Surgical powder. A total of three (1.9%) high-risk patients developed postoperative wound complications (SSI or dehiscence). All complications resolved with local wound care and oral antibiotics; no hospital readmissions were required. This low incidence of surgical complications further supports the use of TIHC as an effective wound therapy agent in spinal surgery.


• Spinal surgery

• Type 1 hydrolyzed collagen

• Surgical site infection

• Wound dehiscence


Hotchkiss WR (2021) Retrospective Study to Evaluate the Use of Type 1 Bovine Hydrolyzed Collagen to Support Surgical Wound Healing After Spinal Surgery. JSM Neurosurg Spine 8(1): 1103.


SSI: Surgical Site Infection, T1HC: Type 1 Hydrolyzed Collagen, EMR: Electronic Medical Records, ECRF: Electronic Case Report Forms


The volume and complexity of spinal surgery cases in the US continues to grow as the aging population increases and healthcare technology continually improves. While wound dehiscence and surgical site infection (SSI) are important concerns after any surgical procedure, following spinal surgery these complications carry considerable morbidity and are associated with long term disability, increased length of stay, and mortality [1]. Treatment of these complications can be challenging, with patients often requiring prolonged antibiotic therapy, multiple revision surgeries, or advanced soft tissue reconstruction [2]. SSI and wound dehiscence are among the most common postoperative spinal surgery complications, and leading causes of 30-day hospital readmissions [2-3]. Incidence rates of SSI have been reported between 0.2% and 16.1%, and vary by type of spinal surgery [4] and patient risk factors including age, diabetes and obesity [2]. Hospital readmission rates are a key quality indicator and many quality improvement measures aim to reduce unnecessary readmissions within 30 days. Effective measures to prevent SSI and wound dehiscence have the potential to improve patient outcomes and prevent unnecessary costs. Supporting the wound healing process is key in preventing infection and complications at the wound site. As early as 1881, exogenous collagen has been used as an adjuvant to enhance surgical wound healing [5]. During the normal wound healing process, proteases degrade and hydrolyze native collagen. The resulting collagen fragments in the wound bed help create a favorable environment to recruit macrophages and fibroblasts, supporting the production of granulation tissue. Collagen-based dressings and powders have shown to be effective wound therapy agents by enhancing the wound healing process. More recently, the use of type 1 hydrolyzed collagen (T1HC) has been used to support the healing environment of surgical wounds. T1HC can be extracted from a variety of animal sources and tissue types, and has demonstrated human biocompatibility in culture [6]. When used for wound therapy, these low molecular weight peptides (3-6 KDa) bypass the need for breakdown by endogenous enzymes, allowing for immediate signaling [7]. CellerateRX ® Surgical (CellerateRX ® Surgical Powder; Sanara MedTech, Fort Worth, TX) is T1HC, FDA cleared for use in the management of acute and chronic wounds including surgical wounds, traumatic wounds, full thickness wounds, venous stasis ulcers, arterial ulcers, diabetic ulcers, first and second degree burns, and superficial wounds. CellerateRX ® Surgical is not indicated for third degree burns. Hospitals have incorporated T1HC in the care of surgical wounds to support an environment conducive for wound healing and potentially reduce complications associated with surgically-induced wounds. This study is a retrospective review of patients who underwent spinal surgery using CellerateRX ® Surgical powder (T1HC) at one orthopedic center in the Southwest. Incidence of surgical site complications (wound dehiscence and SSI) was evaluated.


This study was a retrospective review of medical records from one orthopedic operative center to evaluate surgical site complications in adult patients who underwent spinal surgery with confirmed use of CellerateRX ® Surgical Powder between July 1, 2017 and June 26, 2019. During surgery, CellerateRX ® Surgical powder was used according to the FDA-approved package insert, with one to five grams used depending on would size and depth per surgeon judgement along with vancomycin powder. The study was Seemed exempt by Advarra Institutional Review Board and a waiver of informed consent was granted. Study procedures were limited to the review of existing electronic medical records (EMR). A query of the Investigator’s EMR database for patients aged > 18 years who underwent spinal surgery to correct spinal deformity, or to treat spinal fracture or a degenerative condition with confirmed use of CellerateRX ® Surgical powder during the study timeframe was conducted. Patients who returned for at least one post-surgical follow up visit & gt; 2 weeks and < 6 weeks following surgery were eligible for inclusion in the study. Surgical site complications of wound dehiscence and SSI were evaluated post-surgery through the 6-week post-surgical visit. Details including whether the infection was superficial or deep (using CDC definitions), and any treatments required were obtained. Patient demographics, operative history, medical history, progress notes, and medication logs were reviewed. Data was de-identified and collected on electronic case report forms (eCRF) housed on a private server. Statistical Analysis Rates of surgical site complications (wound dehiscence and SSI) and time to wound resolution data were calculated for all subjects. Patient demographics, baseline characteristics, and surgery characteristics data were summarized. For continuous data, the descriptive summary statistics of n, mean, median, standard deviation, min, and max were calculated. For categorical data, frequency counts and percentages were presented.


One hundred fifty-four (154) patients met study criteria and were included in the analysis. Patient demographics are listed in [Table 1].

Table 1: Patient Demographics and Baseline Risk Factors.




Age (years)



Body Mass Index (BMI) (kg/m2)








76 (49.4%)



78 (50.6%)






145 (94.2%)



7 (4.5%)



2 (1.3%)





Hispanic or Latino

7 (4.5%)


Not Hispanic or Latino

147 (95.5%)

Positive history of diabetes


30 (19.5%)

Current smoker or history of smoking


15 (9.7%)

Concomitant medication use





13 (8.4%)



3 (1.9%)




Mean or N (%)

Abbreviations: BMI=Body Mass Index

The age of patients enrolled ranged from 18 to 82 years; half of the patients were female and half were male. Surgical characteristics are included in [Table 2].

Table 2: Spinal Surgery Characteristics.



N (%)




Reason for surgery





35 (22.7%)



112 (72.7%)



6 (3.9%)



1 (0.6%)

Location of surgery





20 (13.0%)



120 (77.9%)



14 (9.1%)

Surgical approach





8 (5.2%)



146 (94.8%)

Revision Surgery





71 (46.1%)

Spinal Fusion





143 (92.9%)

If fusion, number of levels






34 (23.8%)



37 (25.9%)



20 (14.0%)



12 (8.4%)



5 (3.5%)



7 (4.9%)



9 (6.3%)



8 (5.6%)



11 (7.7%)

The majority of surgeries were lumbar surgeries (77.9%), due to degenerative condition (72.7%), and used a posterior surgical approach (94.8%). Nearly half of surgeries were revisions of previous surgeries. The majority of patients underwent spinal fusions (92.9%), ranging from 1 to 14 levels fused, with a median of 3 levels. All patients included in the analysis were treated with CellerateRX ® Surgical powder. Overall, SSI occurred in 1 patient (0.6%), and wound dehiscence occurred in 3 patients (1.9%) (Figure 1).

Figure 1 Incidence of postsurgical complications of surgical site infection and wound dehiscence

Figure 1 Incidence of postsurgical complications of surgical site infection and wound dehiscence

The case of SSI was preceded by wound dehiscence, so overall 3 patients experienced postsurgical complications. To aid in assessing individual risk factors, details of these 3 patients are described below: A 66 year-old female with a history of diabetes, osteoporosis and scleroderma, with current use of corticosteroids and BMI of 35 kg/mm 2 underwent spinal fusion (2 levels) in the lumbar region using a posterior approach for a degenerative condition. Twenty-eight (28) days after surgery, mild wound dehiscence was noted and resolved with local woundcare. An 81 year-old female with a history of coronary artery disease, hypertension, and Parkinson’s disease with BMI of 23.0 kg/mm 2 underwent spinal fusion (2 levels) in the cervical region using a posterior approach due to trauma. Fourteen (14) days after surgery, mild wound dehiscence was noted and treated with local wound care. Forty-one (41) days after surgery, a superficial SSI infection was noted and treated with local wound care. The wound dehiscence and superficial SSI resolved with local wound care. A 73 year-old female with a history of diabetes, scleroderma and osteoporosis with BMI of 44 kg/mm 2 underwent spinal fusion (2 levels) in the lumbar region using a posterior approach as revision surgery for a degenerative condition. Eighteen (18) days after surgery, mild wound dehiscence was noted and resolved following treatment with oral antibiotics and local wound care. This retrospective analysis of spinal surgery patients supports the effectiveness of CellerateRX ® Surgical powder for surgical wound management in high-risk patients. Only three study patients total (1.9%) in this medically complex surgical population experienced SSI or wound dehiscence, with only 1 patient (0.6%) experiencing an SSI. Zhou et al found a pooled SSI incidence rate of 3.1% in 22,475 patients across 27 studies [4]. A case review of 99,152 spine surgery cases found that 2.2% patients experienced at least one wound complication (SSI or dehiscence) with over half of the complications (1.2%) either a deep or organ space SSI [1]. This review also showed that 46% of the patients who experienced wound dehiscence also had a concomitant SSI. The overall complication rate in the current study using CellerateRX ® Surgical powder was lower than rates reported in the literature, and the events were of lower severity with no deep or organ space SSI. Additionally, only one of the three patients with dehiscence experienced a concomitant SSI. Results of the current study are consistent with results shown by Dickerman et al, who followed 102 consecutive neurosurgery cases for at least 16 weeks [8]. CellerateRX ® Surgical powder and vancomycin power were used during the surgical procedure, and study results showed no cases of wound dehiscence or infection. The authors stated that previous studies using only topical antibiotic powder lowered SSI rates but did not eradicate them [9-10]. and that the unique biochemical design of CellerateRX ® Surgical powder supported wound healing and contributed to prevention of post-surgical complications. Preoperative characteristics associated with wound complications include BMI & gt; 30, female, smoker, chronic steroid use, emergency surgery and operation time >3 hours [1]. Corticosteroids have anti-inflammatory properties and therefore chronic use can be common in the population undergoing spinal surgery. However, they also have immunosuppressive properties, and have been associated with increased risk of infection and delayed wound healing [11]. The population enrolled in the current study had a mean BMI of 30.1 kg/mm 2 , half were female, and a third were complex surgeries involving fusion of more than more than 3 levels. Even with these risk factors, the rate of postsurgical complications was extremely low in this complex surgical population. The study results support previously identified risk factors for postoperative complications; the three patients who experienced SSI or wound dehiscence were female, two were obese and had diabetes, one was currently using corticosteroids, and one was 82 years old and required surgery due to trauma. Wound complications in the study were managed by outpatient wound care and oral antibiotics, and none of the patients required readmission for further treatment. Readmission rates after spinal surgery reported in the literature vary from 7.3-21.3% and increase with age, comorbidities, and surgical complexity [3]. A retrospective review of 14,939 patients showed a readmission rate of 5.5% after instrumented spine surgery, with SSI identified as a leading cause for readmission [3]. SSIs in neurosurgery patients have been reported as the highest costs of all specialtybased SSIs, on average contributing excess costs of $23,755 per case [1]. In the current study, no patients with SSI or dehiscence required readmission, which could provide a cost-savings in addition to benefit to patients.


In the present study, patients who underwent spinal surgery using CellerateRX ® Surgical powder had a low incidence of post-surgical wound complications including SSI and dehiscence supporting its use as an effective wound therapy agent. All three patients who developed SSI or wound dehiscence were high risk and treatment included oral antibiotics and outpatient wound care only; no patients required readmission. Limitations of this study include that it was performed at a single site and there was no control group for comparison.


1. Piper KF, Tomlinson SB, Santangelo G, Van Gelen J, DeAndrea-Lazarus I, Towner J, et al. Risk factors for wound complications following spine surgery. Surg Neurol Int. 2017; 8: 269.

2. Yao R, Zhou H, Choma TJ, Kwon BK, Street J. Surgical Site Infection in Spine Surgery: Who Is at Risk?. Global Spine J. 2018; 8: 5S-30S.

3. Akins PT, Harris J, Alvarez JL, Chen Y, Paxton EW, Bernbeck J, et al. Risk Factors Associated With 30-day Readmissions After Instrumented Spine Surgery in 14,939 Patients: 30-day readmissions after instrumented spine surgery. Spine (Phila Pa 1976) 2015; 40: 1022-1032.

4. Zhou J, Yuan Xue, Liang Kang, Wuyi Xiong, Xiaoyang Huo, et al. Incidence of Surgical Site Infection After Spine Surgery: A Systematic Review and Meta-analysis. Spine 2020; 45: 208-216.

5. Chattopadhyay S, Raines RT. Review collagen-based biomaterials for wound healing. Biopolymers. 2014; 101: 821-833.

6. Qureshi A, Murphy E, Milando R, Rengifo-Pardo M, Clayton C, et al. A Head-to-Head Comparison of Topical Collagen Powder to Primary Closure for Acute Full-Thickness Punch Biopsy-Induced Human Wounds: An Internally Controlled Pilot Study. J Drugs Dermatol. 2019; 18: 667-673.

7. Kallis J. Collagen Powder in Wound Healing. Drugs Dermatol. 2018; 17: 403-408.

8. Dickerman R, Reynolds AS, Winters K. Operative closure technique utilizing bovine collagen fragments in a prospective analysis of 102 consecutive neurosurgery patients. JSM Neurosurg Spine. 2017; 5: 1088.

9. Beckman JM, Amankwah EK, Tetreault LL, Tuite GF. Reduction in CSF shunt infection over a 10-year period associated with the application of concentrated topical antibiotic powder directly to surgical wounds prior to closure. J Neurosurg Pediatric. 2015; 16: 648-661.

10.Dennis HH, Wei DT, Darren KZ, Shantakumar JT, Kumar N, Lau LL, et al. Is Intraoperative Local Vancomycin Powder the Answer to Surgical Site Infections in Spine Surgery? Spine (Phila Pa 1976). 2016; 42: 267- 274.

11.Youssef J, Novosad SA, Winthrop KL. Infection Risk and Safety of Corticosteroid Use. Rheum Dis Clin North Am. 2016; 42: 157-176.

Received : 05 Oct 2021
Accepted : 11 Nov 2021
Published : 15 Nov 2021
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X